N-(3-Oxooctanoyl)-DL-homoserine lactone | CAS:106983-27-1

We serve N-(3-Oxooctanoyl)-DL-homoserine lactone CAS:106983-27-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
N-(3-Oxooctanoyl)-DL-homoserine lactone

Chemical Name:N-(3-Oxooctanoyl)-DL-homoserine lactone
CAS.NO:106983-27-1
Synonyms:N-(3-Oxooctanoyl)-DL-homoserine lactone
3-oxo-N-(2-oxooxolan-3-yl)octanamide
3-Oxo-N-(tetrahydro-2-oxo-3-furanyl)-octanamide
3-oxooctanoylhomoserine lactone
 
Physical and Chemical Properties:
Molecular Formula C12H19NO4
Molecular Weight 241.28400
Exact Mass 241.13100
PSA 72.47000
LogP 1.34850
 
Specification:
Appearance:White to light yellow crystalline powder
Assay:≥95.0%
 
Packing:5 g/bag, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Organic synthesis.



Contact us for information like N-(3-Oxooctanoyl)-DL-homoserine lactone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-oxooctanoylhomoserine lactone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-oxo-N-(2-oxooxolan-3-yl)octanamide Use and application,3-oxo-N-(2-oxooxolan-3-yl)octanamide technical grade,usp/ep/jp grade.


Related News: In China, Wuhan used to be known as a city of cherry blossoms, an economic engine of the central heartland, and the birthplace of a century-old revolution that brought down the country’s last imperial dynasty.[Zr(tropocoronand-3,3)(benzyl)2] manufacturer In China, Wuhan used to be known as a city of cherry blossoms, an economic engine of the central heartland, and the birthplace of a century-old revolution that brought down the country’s last imperial dynasty.4-(6,11-dioxo-6,11-dihydro-benzo[f]pyrido[1,2-a]indole-12-carbonylamino)-benzoic acid supplier “CAR T-cell therapy continues to deliver remarkable outcomes for patients with hematologic malignancies, and next-generation approaches are needed to enable broad and timely patient access and reduce the cost and complexity of therapy,” said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.4-ethylamino-2H-phthalazin-1-one vendor We are pleased to work with Inceptua, given their strong record of administering such programs successfully.”With the structural upgrade of the pharmaceutical industry in developed countries, the transfer of related industrial chains has taken place globally, and it has also had a profound impact on Chinese pharmaceutical companies. near